Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 7:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 960 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 4 & 2 & 1 Plan Clear all
Recruiting Phase 1 Interventional

Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab

NCT06447376
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Interventions
Siltuximab, Epcoritamab, Gemcitabine and oxaliplatin
Drug
Lead sponsor
Taylor Brooks
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Not applicable Interventional Results available

Acceptability and Feasibility of Cognitive Behavioral Therapy for Treatment-Seeking (CBT-TS) With Deaf Individuals

NCT05520190
View directory record Official record
Conditions
Mental Health Issue, Alcohol Use Disorder, Depression, Anxiety, Insomnia, Post Traumatic Stress Disorder
Interventions
Cognitive Behavioral Therapy for Treatment Seeking (CBT-TS)
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 2 Interventional Results available

CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS

NCT03401190
View directory record Official record
Conditions
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
Interventions
CM4620 Injectable Emulsion (Low Dose), CM4620 Injectable Emulsion (High Dose)
Drug
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Detroit, Michigan • Minneapolis, Minnesota • Saint Paul, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Terminated Not applicable Interventional Results available

Proton Beam Therapy in the Treatment of Esophageal Cancer

NCT03482791
View directory record Official record
Conditions
Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
Interventions
Proton beam therapy, Patient-Reported Outcome Measures
Radiation · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Completed No phase listed Observational

Study in Patients With Unresectable And Metastatic Melanoma: The Optimize Study

NCT02780089
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
66
States / cities
Muscle Shoals, Alabama • Hot Springs, Arkansas • Long Beach, California + 59 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Connecting Healthy Women: Examining the Effect of an Intervention From the Effect of Being Reachable

NCT02157168
View directory record Official record
Conditions
Contraception, Sexually Transmitted Infections, Cervical Cancer
Interventions
Community health worker
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
2,267 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 5, 2019 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

NCT01167868
View directory record Official record
Conditions
Healthy
Interventions
FosD, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 7, 2013 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Not applicable Interventional

Laser Hair Removal for Treatment of Pilonidal Disease

NCT03949140
View directory record Official record
Conditions
Pilonidal Disease
Interventions
Laser hair removal
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
13 Years to 35 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 7, 2026, 7:05 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Using EMA Data to Inform a Web-intervention for Couples Concerned About Drinking

NCT06501677
View directory record Official record
Conditions
Alcohol; Use, Problem
Interventions
WBI
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Addressing Prostate Cancer Information Disparities With eHealth Technology

NCT02787434
View directory record Official record
Conditions
Prostate Neoplasm
Interventions
Prostate Cancer Screening Decision Aid
Other
Lead sponsor
Tufts University
Other
Eligibility
45 Years to 70 Years · Male only
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Medford, Massachusetts • Atlanta, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 7, 2026, 7:05 AM EDT
Terminated Phase 2Phase 3 Interventional

The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade Glioma

NCT02414165
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Toca 511, Toca FC, Lomustine, Temozolomide, Bevacizumab
Biological · Drug
Lead sponsor
Tocagen Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
50
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 41 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 7, 2026, 7:05 AM EDT
Active, not recruiting Phase 1 Interventional

Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors

NCT02498912
View directory record Official record
Conditions
Solid Tumors
Interventions
Production of Genetically-modified T cells, Cyclophosphamide, IP Catheter Insertion, Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells, Fludarabine
Procedure · Drug · Device + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Not applicable Interventional

Care Transition Intervention for Hospitalized Patients With Advanced Cancer

NCT05142345
View directory record Official record
Conditions
Cancer, Follow-Up Care, Consultation, Remote, Advanced Cancer
Interventions
CONTINUUM Intervention, Usual Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 7, 2026, 7:05 AM EDT
Active, not recruiting Phase 1 Interventional

A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer

NCT04092270
View directory record Official record
Conditions
Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Undifferentiated Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Low Grade Serous Adenocarcinoma, Recurrent Ovarian Malignant Mixed Mesodermal (Mullerian) Tumor, Recurrent Ovarian Mucinous Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Pegylated Liposomal Doxorubicin Hydrochloride, Peposertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Boston, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Recruiting No phase listed Observational

Depression and Driving

NCT05446805
View directory record Official record
Conditions
Depression, Drive
Interventions
F 18 AV-1451 (Flortaucipir), [11C]-Pittsburgh Compound B ([11C]PiB)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
65 Years and older
Enrollment
150 participants
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Withdrawn Phase 2 Interventional

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

NCT06352866
View directory record Official record
Conditions
Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Siltuximab, Teclistamab(FDA-approved)
Drug
Lead sponsor
Jack Khouri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 7, 2026, 7:05 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study Involving SAB01 and Healthy Participants

NCT07815561
View directory record Official record
Conditions
Healthy Adult Participants
Interventions
Subcutaneous (SC) single dose of SAB01, Intravenous (IV) infusion of SAB01, Placebo SC, Placebo IV Infusion
Drug
Lead sponsor
Santa Ana Bio
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Active, not recruiting Not applicable Interventional

Becoming United in Lifestyle Decisions

NCT05796141
View directory record Official record
Conditions
Overweight and Obesity
Interventions
Core Behavioral Weight Loss (BWL) intervention, Dyadic Action Planning, Joint Feedback, Autonomy Support Training, Home Environment Modifications
Behavioral
Lead sponsor
University of Connecticut
Other
Eligibility
18 Years to 75 Years
Enrollment
762 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Hormonal Regulation of Postpartum Weight and Presence of Gut Peptides in Human Milk

NCT01514539
View directory record Official record
Conditions
Maternal Obesity Syndrome
Interventions
cross-sectional
Other
Lead sponsor
University of Wyoming
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Laramie, Wyoming
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Examining Community-based Effectiveness of a Substance Use and HIV Risk Reduction Intervention for Young Men of Color

NCT03488914
View directory record Official record
Conditions
Substance Use, Sexual Risk
Interventions
YMHP Intervention, Enhanced Treatment as Usual
Behavioral
Lead sponsor
Hunter College of City University of New York
Other
Eligibility
15 Years to 29 Years · Male only
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
2
States / cities
Brooklyn, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 7, 2026, 7:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Families Preventing Diabetes Together

NCT02721602
View directory record Official record
Conditions
Type 2 Diabetes, Pediatric Obesity
Interventions
Families Preventing Diabetes Together
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
2 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 7, 2026, 7:05 AM EDT
Active, not recruiting No phase listed Observational

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment

NCT05926024
View directory record Official record
Conditions
Breast Cancer
Interventions
Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
Behavioral · Diagnostic Test
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 7, 2026, 7:05 AM EDT
Terminated Phase 2 Interventional Results available

Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma

NCT01886105
View directory record Official record
Conditions
Metastatic Osteosarcoma
Interventions
Sm-EDTMP, Autologous Stem Cell Infusion, External Beam Radiotherapy
Drug · Other · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
10 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 7, 2026, 7:05 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Balancing Emotions and Electronics: A Pilot Intervention for Preschoolers

NCT07394166
View directory record Official record
Conditions
Screen Media Use
Interventions
Brief-RSU
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Months to 54 Months
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 7, 2026, 7:05 AM EDT